Jon Congleton - Nov 11, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Nov 11, 2025
Transactions value $
-$9,088,499
Form type
4
Date filed
11/13/2025, 07:01 PM
Previous filing
Oct 15, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Congleton Jon Chief Executive Officer, Director 150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 2025-11-13 0001644975

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Sale -$533K -12.8K -1.54% $41.64 818K Nov 11, 2025 Direct F1
transaction MLYS Common Stock Sale -$375K -8.86K -1.08% $42.31 810K Nov 11, 2025 Direct F2
transaction MLYS Common Stock Sale -$174K -4K -0.49% $43.50 806K Nov 11, 2025 Direct F3
transaction MLYS Common Stock Sale -$1.32M -29.2K -3.63% $45.20 776K Nov 11, 2025 Direct F4
transaction MLYS Common Stock Sale -$5.15M -112K -14.46% $45.83 664K Nov 11, 2025 Direct F5
transaction MLYS Common Stock Sale -$1.54M -32.9K -4.95% $46.89 631K Nov 11, 2025 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0500 to $42.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.0500 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4800 to $45.4297. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4300 to $46.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4400 to $47.4191. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.